Hemoglobin News and Research RSS Feed - Hemoglobin News and Research

Study: Umbilical cord milking improves blood pressure, red blood cell levels in preterm infants

Study: Umbilical cord milking improves blood pressure, red blood cell levels in preterm infants

A technique to increase the flow of blood from the umbilical cord into the infant's circulatory system improves blood pressure and red blood cell levels in preterm infants delivered by Cesarean section, according to a study funded by the National Institutes of Health. [More]
New report on global market for point of care diagnostics

New report on global market for point of care diagnostics

The market for point of care diagnostics reached $17 billion, in 2014, according to Kalorama Information. The term refers to diagnostic tests performed outside the central laboratory or decentralized. [More]
Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. [More]
New UT Southwestern research shows that exercise can improve diabetes control

New UT Southwestern research shows that exercise can improve diabetes control

Diabetics who exercise can trim waist size and body fat, and control blood glucose, even if they don't see cardiorespiratory benefits, new research by UT Southwestern Medical Center cardiologists shows. [More]
FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. [More]
Point of care measurement of hemoglobin: an interview with Katja Lemburg, EKF Diagnostics

Point of care measurement of hemoglobin: an interview with Katja Lemburg, EKF Diagnostics

Katja Lemburg discusses the next generation Hemo Control being launched in Europe at EuroMedLab, Paris 21-25th June. EKF will be exhibiting on Stand G005 (Level 1). [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Day in and day out, for years on end, millions of people with diabetes prick their fingers to test their blood sugar level. And many may wonder if all the careful eating, exercise and medication it takes to keep those levels under control is really worth it. [More]
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. [More]
Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors. [More]
Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. [More]
Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR. [More]
OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis. [More]
Functional foods help reduce obesity, control diabetes

Functional foods help reduce obesity, control diabetes

The so called functional foods such as cactus pads, chia and soybean, when included in a balanced diet, help reduce obesity and control diabetes, says Nimbe Torres y Torres, from the Institute of Biomedical Research at the National Autonomous University of Mexico. [More]
Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

Carbon monoxide may actually protect the brain from damage after subarachnoid hemorrhage

Carbon monoxide is known by many as a poisonous gas that causes brain injury and other neurological symptoms, including memory loss and confusion. But a new study led by investigators at Beth Israel Deaconess Medical Center suggests the opposite may be true: When administered in small, carefully controlled amounts, carbon monoxide may actually protect the brain from damage following subarachnoid hemorrhage, a devastating stroke that results from bleeding in the brain. [More]
Treatment outcomes in type 1 diabetes could be improved across all age groups

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults. [More]
Shiftworkers more likely to develop metabolic disorders

Shiftworkers more likely to develop metabolic disorders

Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status. [More]
AMC Health to collaborate with URAC on national telehealth standards development initiative

AMC Health to collaborate with URAC on national telehealth standards development initiative

AMC Health, a leading provider of 'real-time' patient management solutions has announced that it will collaborate with URAC on its national telehealth standards development initiative. [More]
Researchers reveal potential mode of drug resistance in malaria parasites

Researchers reveal potential mode of drug resistance in malaria parasites

Scientists have uncovered a potential mode of parasite drug resistance in malaria infection, according to a report published in The Journal of Experimental Medicine. [More]
Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy [More]
Advertisement
Advertisement